Preliminary studies in human DLBCL suggest factors such as molecular subtype (ABC vs. GCB) as well as specific mutations (MYD88, CD79, CARD11 and TNFAIP3) may predict response to ibrutinib [10,11]. This evidence concerns the gene CARD11 and diffuse large B-cell lymphoma.